Duyuru • Jul 08
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio Bio-Techne Corporation announced the launch of new additions to its R&D Systems AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents. By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes. These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing. The newly launched proteins include: FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. FGF-7 Heat Stable – Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. FGF-8b Heat Stable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. IL-3 Heat Stable – Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. IL-15 Hyperactive – Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success. Duyuru • Jun 27
Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH) for $11.5 billion. Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH) for $11.5 billion on June 25, 2026. Merck KGaA will acquire Bio-Techne for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion (€9.9 billion). The planned acquisition will be funded through a combination of existing cash on hand and proceeds from new debt.
The transaction is subject to approval of merger agreement by target board, approval by regulatory board / committee and approval of offer by target shareholders, subject to satisfaction of customary closing conditions. The proposed transaction has been approved by Bio-Techne's Board of Directors. The transaction is expected to close by late 2026 or early 2027. The proposed transaction is expected to be immediately accretive to EBITDA pre margin of both Life Science and the Group post-closing and EPS pre accretive by year 3 after closing. Cost synergies of approximately $159.6 million (€140 million) are expected to be fully realized by year 3 after closing.
Guggenheim Securities, LLC acted as financial advisor for Merck KGaA. J.P. Morgan Securities, Inc. acted as financial advisor for Merck KGaA. Sullivan & Cromwell LLP acted as legal advisor to Merck KGaA. Goldman Sachs & Co. LLC acted as financial advisor for Bio-Techne Corporation. Sidley Austin LLP acted as legal advisor for Bio-Techne Corporation. Buy Or Sell Opportunity • Jun 26
Now 38% overvalued after recent price rise Over the last 90 days, the stock has risen 40% to €62.78. The fair value is estimated to be €45.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has declined by 43%. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Duyuru • May 07
Bio-Techne Corporation announces Quarterly dividend, payable on May 29, 2026 Bio-Techne Corporation announced Quarterly dividend of USD 0.0800 per share payable on May 29, 2026, ex-date on May 18, 2026 and record date on May 18, 2026. Duyuru • Apr 18
Bio-Techne Corporation Introduces Streamlined Brand Architecture With Three Portfolio Brands Bio-Techne Corporation announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research. The company has organized its products and technologies under three focused portfolio brands -- R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ -- aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics. The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™. The R&D Systems portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows. The Bio-Techne Spatial portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery. The Bio-Techne Diagnostics portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision-making, and ultimately contributes to improved patient outcomes. Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end-to-end view of Bio-Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress. R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls. Duyuru • Mar 25
Bio-Techne Corporation Expands Comet Solution Portfolio with Addition of Spyre Focus Panels and Spyre Amplification Kits Bio-Techne Corporation announced the expansion of its COMET solution portfolio with the addition of the new SPYRE Focus Panels and SPYRE Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. SPYRE Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE Amplification Kits use seqLA technology to improve the detection of low-abundance and difficult-to-detect targets. Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample. 
